SALIRASIB
Salirasib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target transient receptor potential cation channel subfamily A member 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
20 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 1 | — | — | — | — | 1 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
| Hematologic neoplasms | D019337 | — | — | 1 | — | — | — | — | 1 |
| Preleukemia | D011289 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 3 | 3 |
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | — | — | — | 2 | 2 |
| Opiate overdose | D000083682 | — | — | — | — | — | — | 2 | 2 |
| Drug overdose | D062787 | — | — | — | — | — | — | 2 | 2 |
| Harm reduction | D040261 | — | — | — | — | — | — | 2 | 2 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | — | 2 | 2 |
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | — | — | — | — | 1 | 1 |
| Eclampsia | D004461 | — | O15 | — | — | — | — | 1 | 1 |
| Digeorge syndrome | D004062 | — | D82.1 | — | — | — | — | 1 | 1 |
| Trisomy | D014314 | — | Q92.2 | — | — | — | — | 1 | 1 |
Show 23 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | SALIRASIB |
| INN | salirasib |
| Description | Salirasib is a sesquiterpenoid. |
| Classification | Small molecule |
| Drug class | Kirsten rat sarcoma (KRAS) inhibitors; anti-inflammatory agents (salicylic acid derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)=CCC/C(C)=C/CC/C(C)=C/CSc1ccccc1C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 162520-00-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL23293 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB12681 |
| UNII ID | MZH0OM550M (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
TRPA1
TRPA1
Organism
Homo sapiens
Gene name
TRPA1
Gene synonyms
ANKTM1
NCBI Gene ID
Protein name
transient receptor potential cation channel subfamily A member 1
Protein synonyms
ankyrin-like with transmembrane domains 1, Ankyrin-like with transmembrane domains protein 1, p120, Transformation-sensitive protein p120, Wasabi receptor
Uniprot ID
Mouse ortholog
Trpa1 (277328)
transient receptor potential cation channel subfamily A member 1 (Q8BLA8)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,711 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
16 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use